Literature DB >> 32020729

Incorporation of Pseudo-complementary Bases 2,6-Diaminopurine and 2-Thiouracil into Serinol Nucleic Acid (SNA) to Promote SNA/RNA Hybridization.

Yukiko Kamiya1, Fuminori Sato1, Keiji Murayama1, Atsuji Kodama2, Susumu Uchiyama2,3, Hiroyuki Asanuma1.   

Abstract

Serinol nucleic acid (SNA) is a promising candidate for nucleic acid-based molecular probes and drugs due to its high affinity for RNA. Our previous work revealed that incorporation of 2,6-diaminpurine (D), which can form three hydrogen bonds with uracil, into SNA increases the melting temperature of SNA-RNA duplexes. However, D incorporation into short self-complementary regions of SNA promoted self-dimerization and hindered hybridization with RNA. Here we synthesized a SNA monomer of 2-thiouracil (sU), which was expected to inhibit base pairing with D by steric hindrance between sulfur and the amino group. To prepare the SNA containing D and sU in high yield, we customized the protecting groups on D and sU monomers that can be readily deprotected under acidic conditions. Incorporation of D and sU into SNA facilitated stable duplex formation with target RNA by suppressing the self-hybridization of SNA and increasing the stability of the heteroduplex of SNA and its complementary RNA. Our results have important implications for the development of SNA-based probes and nucleic acid drugs.
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  2,6-diaminopurine; 2-thiouracil; acyclic nucleic acid; pseudo complementary base; serinol nucleic acid

Year:  2020        PMID: 32020729     DOI: 10.1002/asia.201901728

Source DB:  PubMed          Journal:  Chem Asian J        ISSN: 1861-471X


  1 in total

1.  A Chemical Approach to Introduce 2,6-Diaminopurine and 2-Aminoadenine Conjugates into Oligonucleotides without Need for Protecting Groups.

Authors:  Mimouna Madaoui; Dhrubajyoti Datta; Kelly Wassarman; Ivan Zlatev; Martin Egli; Bruce S Ross; Muthiah Manoharan
Journal:  Org Lett       Date:  2022-08-16       Impact factor: 6.072

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.